ABSTRACT
BACKGROUND: Vascular disease is a common cause of death in patients with chronic hepatitis C (CHC) infection; however, the association between CHC and atherosclerosis is unclear. AIMS: To determine whether patients with CHC have increased subclinical vascular disease and whether genotype or antiviral treatment modifies this risk. METHODS: Fifty CHC patients and 22 age-matched and sex-matched healthy controls underwent clinical and biochemical assessment for vascular risk factors. In addition, vascular risk was assessed by measuring arterial stiffness (aortic augmentation index and carotid-femoral pulse wave velocity (PWV)), endothelial dysfunction (brachial artery flow-mediated dilatation (FMD) and dilatation post-glycerol trinitrate administration) and carotid intima-media thickness (CIMT). Assessment was repeated in subset of CHC patients (n = 12) undergoing antiviral treatment 18 months after initiation of treatment. RESULTS: Baseline vascular risk factors and measures of arterial stiffness, endothelial dysfunction and CIMT were not different between cases and controls (P > 0.2 for all). Genotype 1 CHC patients had greater endothelial dysfunction with lower FMD (8.2 ± 3.5% vs 10.9 ± 5.2%, P = 0.03) and higher right CIMT (0.6 ± 0.1 mm vs 0.5 ± 0.07 mm, P = 0.04) compared with non-genotype 1. Patients who achieved sustained virological response (7/12) showed significant improvement in insulin resistance (homeostasis model of assessment of insulin resistance 2.3 ± 1.2 vs 1.8 ± 0.8, P = 0.02) and arterial stiffness (PWV 7.4 ± 1.1 m/s vs 6.5 ± 0.6 m/s, P = 0.04). CONCLUSIONS: Subclinical vascular disease is not greater in CHC subjects compared with controls. However, among CHC subjects, genotype 1 infection is associated with greater endothelial dysfunction and increased carotid-intima medial thickness compared with non-genotype 1 infection. Successful viral eradication may improve insulin resistance and arterial stiffness.
Subject(s)
Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Carotid Intima-Media Thickness , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/epidemiology , Adult , Case-Control Studies , Cross-Sectional Studies , Female , Humans , Longitudinal Studies , Male , Middle Aged , Risk Factors , Vascular Stiffness/physiologyABSTRACT
BACKGROUND AND AIMS: Rates of long-term clinical outcomes of chronic hepatitis C in patients with none, mild or severe liver fibrosis are required to determine benefits of anti-viral therapies. This study evaluated long-term outcomes for chronic hepatitis C stratified by all Metavir fibrosis stages. METHODS: Clinical outcomes were determined using population-based data linkage methodology for 880 hepatitis C patients who had a liver biopsy performed from 1992 to 2012. RESULTS: During 9386 person-years of follow up, 28 patients developed hepatocellular carcinoma, 58 developed liver decompensation and 122 died or underwent liver transplantation. There was no significant difference in liver-related death for those with F0-F2 with an 18-year survival probability >94%. Hazard ratio of liver-related death for F3 compared with F0-F2 was 4.24 (P = 0.003), with no significant difference in the first 13-year follow up. The 15-year decompensation-free survival for F0, F1 and F2 was 100%, 96% and 94% respectively and for hepatocellular carcinoma-free survival was 100%, 99% and 98%. Hazard ratio of liver complication (hepatocellular carcinoma or decompensation)-free survival for F3 compared with F0-F2 was 3.22 (P = 0.001), with no significant difference during the first 7-year follow up. F4 had significantly higher risk of liver-related death, decompensation and hepatocellular carcinoma than F3 (P < 0.001). CONCLUSIONS: Chronic hepatitis C patients with F2 or less had few liver complications after 15 years. For F3 patients, the significant increase in liver-related death occurred after 13 years and for liver complications after 7 years.
Subject(s)
Carcinoma, Hepatocellular/etiology , Hepatitis C, Chronic/complications , Hospitals/statistics & numerical data , Liver Cirrhosis/etiology , Liver Neoplasms/etiology , Liver Transplantation/statistics & numerical data , Adult , Aged , Aged, 80 and over , Biopsy , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/epidemiology , Disease Progression , Female , Follow-Up Studies , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/surgery , Humans , Incidence , Liver/pathology , Liver Cirrhosis/diagnosis , Liver Cirrhosis/epidemiology , Liver Neoplasms/diagnosis , Liver Neoplasms/epidemiology , Male , Middle Aged , Retrospective Studies , Survival Rate/trends , Western Australia/epidemiologyABSTRACT
Thrombotic microangiopathy (TMA) is a potentially fatal complication in solid organ and bone marrow transplant patients, with reported incidence of 0.5-3% and mortality of about 75%. To emphasise the importance of early diagnosis and prompt commencement of therapy results in improved clinical outcomes. A retrospective study of all patients who underwent orthotopic liver transplantation (OLTX) at the Western Australian Liver Transplantation Service from May 1994 to December 2010 was conducted to identify patients who developed tacrolimus-induced TMA. We identified four patients with tacrolimus-induced TMA post-OLTX, derived from a cohort of 104 patients treated with tacrolimus in our institution. The mean age at diagnosis was 40 years, and the mean time of onset was 63 ± 7.5 weeks after OLTX. The indications for OLTX in the four patients were fulminant hepatic failure in three (Wilson disease, paracetamol overdose and post-partum thrombotic thrombocytopenic purpura) and hepatitis C virus-related cirrhosis. All patients had tacrolimus post-OLTX. At diagnosis, tacrolimus was discontinued in all patients, and three of the four patients underwent plasma exchange and all patients improved clinically. Mean duration of follow up was 15 ± 7.5 months. There was no mortality 6 months post-TMA. Early diagnosis with immediate discontinuation or conversion of calcineurin inhibitors and plasma exchange should be offered to OLTX patients with TMA as it results in good outcomes.
Subject(s)
Immunosuppressive Agents/adverse effects , Liver Transplantation/adverse effects , Tacrolimus/adverse effects , Thrombotic Microangiopathies/chemically induced , Thrombotic Microangiopathies/diagnosis , Adult , Cohort Studies , Female , Follow-Up Studies , Humans , Liver Transplantation/methods , Male , Middle Aged , Retrospective Studies , Thrombotic Microangiopathies/immunology , Young AdultABSTRACT
BACKGROUND AND GOALS: Liver fibrosis influences treatment and surveillance strategies in chronic hepatitis B (CHB). This multicenter study aimed to examine the accuracy of serum fibrosis models in CHB patients including those with low alanine aminotransferase (ALT) levels and serially in those undergoing treatment. METHOD: We examined noninvasive fibrosis models [Hepascore, Fibrotest, APRI, hepatitis e antigen (HBeAg)-positive and -negative models] in 179 CHB patients who underwent liver biopsy and fibrosis assessment by METAVIR and image morphometry. Serial Hepascore measurements were assessed in 40 subjects for up to 8.7 years. RESULTS: Hepascore was more accurate than Fibrotest [area under the curve (AUC) 0.83 vs. 0.72, P = 0.05] and HBeAg-positive model (AUC 0.83 vs. 72, P = 0.03) for significant fibrosis but was not significantly different to APRI or HBeAg-negative scores. Fibrosis area assessed by morphometry was correlated with Hepascore (r = 0.603, P < 0.001), Fibrotest (r = 0.392, P = 0.03), and HBeAg-positive (r = 0.492, P = 0.001) scores only. Among 73 patients with an ALT <60 IU/L, noninvasive models were useful to predict fibrosis (PPV 80-90%) or exclude significant fibrosis (NPV 79-100%). Hepascore increased significantly among patients monitored without treatment and reduced among patients undergoing therapy (0.05/year ± 0.03 vs. -0.04/year ± 0.02, P = 0.007). CONCLUSIONS: Serum fibrosis models are predictive of fibrosis in CHB and assist in identifying subjects with low-normal ALT levels for treatment.
ABSTRACT
Iron chelators and antioxidants have been shown to prevent hypothermia-induced apoptosis in hepatocytes. This study examined whether iron chelation and antioxidants could also prevent hypothermia-induced necrosis. Isolated rat hepatocytes were incubated at 4 degrees C for 6 hours and then rewarmed at 37 degrees C for 18 hours with or without the iron chelator deferoxamine and a selection of antioxidants. There was no evidence of increased cell death or adenosine triphosphate depletion during hypothermic incubation. After hypothermia and rewarming, the majority of rat hepatocytes died of necrosis as indicated by the absence of DNA fragmentation, caspase 3 activity, and apoptotic bodies. Cell death was significantly reduced if deferoxamine or a selection of antioxidants were present during hypothermia and rewarming. Deferoxamine was more effective in preventing cell death when added prior to hypothermia, indicating cell death processes were likely initiated during hypothermia.
Subject(s)
Hepatocytes/pathology , Iron/pharmacology , Oxidative Stress/physiology , Adenosine Triphosphate/metabolism , Animals , Apoptosis , Ascorbic Acid/pharmacology , Caspase 3/metabolism , Cell Culture Techniques/methods , Cell Death/drug effects , Hepatocytes/cytology , Hepatocytes/drug effects , Hepatocytes/metabolism , Hypothermia/pathology , L-Lactate Dehydrogenase/analysis , Lactates/metabolism , Necrosis , RatsABSTRACT
BACKGROUND: Hepatic epithelioid haemangioendothelioma (HEH) is a rare, low grade malignant neoplasm of endothelial origin which is difficult to diagnose and has a variable outcome. We review five HEH cases from our centre with the aim of identifying clinical predictors of outcome and various therapeutic options. METHODS: A search was made on the WA Liver Transplant registry for cases with histologically confirmed HEH. Their medical records were reviewed. A literature search was conducted through Medline using terms to compare the results from this series with those of other series. RESULTS: Five patients were identified to have HEH. The mean age was 44.2years (range 34-53years). Four of five patients presented with dyspepsia and two patients had clinical evidence of portal hypertension with ascites. Two patients had radiologically diffuse disease and three patients had discrete nodular liver involvement. The mean duration from presentation of symptoms to diagnosis of HEH was 26.8months. Liver transplantation was performed in one patient with diffuse HEH who is alive with no disease recurrence at 3years. Three patients with radiologically stable disease followed with 6monthly surveillance imaging are currently alive and well. The median survival of all five patients was 5years (range 1.5-16years) at the time of follow up. CONCLUSIONS: These results support the role of surveillance alone for patients with focal and radiologically stable disease. Patients with diffuse HEH with hepatic decompensation should be considered for transplantation. However, numbers are small and an international registry is required to make firm comparisons.
Subject(s)
Hemangioendothelioma, Epithelioid/diagnosis , Hemangioendothelioma, Epithelioid/therapy , Liver Neoplasms/diagnosis , Liver Neoplasms/therapy , Adult , Disease Management , Female , Follow-Up Studies , Humans , Magnetic Resonance Imaging , Male , Middle AgedABSTRACT
A 46-year-old man with cirrhosis secondary to hepatitis C virus infection and alcohol underwent orthotopic liver transplantation, which required urgent re-grafting because of biliary sepsis from necrosis of the left liver lobe. Recovery was complicated by renal failure and nephrogenic systemic fibrosis (probably related to intravenous gadolinium exposure). He subsequently developed a malignant fibrous histiocytoma. We present this case highlighting the occurrence of two rare conditions in the same patient following liver transplantation. We believe this is the first case of its kind to be reported.
Subject(s)
Histiocytoma, Malignant Fibrous/diagnosis , Liver Transplantation/adverse effects , Nephrogenic Fibrosing Dermopathy/diagnosis , Postoperative Complications/diagnosis , Fatal Outcome , Histiocytoma, Malignant Fibrous/complications , Histiocytoma, Malignant Fibrous/therapy , Humans , Male , Middle Aged , Nephrogenic Fibrosing Dermopathy/etiology , Nephrogenic Fibrosing Dermopathy/therapy , Postoperative Complications/therapySubject(s)
Anticonvulsants/adverse effects , Epilepsy/drug therapy , Liver Failure, Acute/chemically induced , Liver/drug effects , Piracetam/analogs & derivatives , Adult , Brain/drug effects , Brain/parasitology , Brain/physiopathology , Epilepsy/parasitology , Humans , Levetiracetam , Liver/physiopathology , Liver Failure, Acute/physiopathology , Liver Failure, Acute/therapy , Liver Function Tests , Liver Transplantation , Male , Neurocysticercosis/complications , Phenytoin/adverse effects , Piracetam/adverse effects , Treatment OutcomeABSTRACT
An 11-year-old boy presented with hepatic failure secondary to parvovirus B19 infection, requiring urgent liver transplantation. His recovery was complicated by primary Epstein-Barr virus and cytomegalovirus infections. He subsequently developed aplastic anaemia that has been refractory to antithymocyte globulin and cyclosporine therapy and may now require bone marrow transplantation. We present this case to emphasize parvovirus as a rare cause of hepatic failure and of aplastic anaemia as a complication of the virus.
Subject(s)
Anemia, Aplastic/complications , Emergency Treatment , Liver Failure, Acute/complications , Liver Failure, Acute/surgery , Liver Transplantation , Virus Diseases/complications , Child , Cytomegalovirus Infections/complications , Epstein-Barr Virus Infections/complications , Humans , Liver/pathology , Liver Failure, Acute/pathology , Male , Parvoviridae Infections/complications , Parvovirus B19, HumanABSTRACT
BACKGROUND: Cytomegalovirus (CMV) following orthotopic liver transplantation can result in significant morbidity and mortality. Prophylaxis with oral aciclovir (ACV) or ganciclovir (GCV) for all transplant recipients (universal prophylaxis) may be beneficial, but which agent is more cost-effective is unknown. METHODS: A single centre, retrospective study of all patients who had OLT at the Western Australian Liver Transplantation Service was performed. Patients received ACV from 1992 to 1998, and GCV from 1999 to 2001. A comparative cost-effectiveness analysis for the two groups was performed based on the mean total cost of the number of cases of CMV infection and disease as the clinical end-point. RESULTS: The ACV group comprised of 55 patients and there were 24 in the GCV group. The incidence of CMV disease was 7% and 4% for the ACV and GCV groups, respectively (P > 0.05). For CMV infection it was 16% and 8%, respectively (P > 0.05). GCV prevented more cases of CMV infection and disease than ACV but at an incremental cost of dollars A20,000 (dollars US10,172) per case prevented. Overall, ACV was more cost-effective than GCV by dollars A2200 (dollars US1119) per person. The cost benefit of ACV was derived principally through a reduced pharmaceutical cost. Both agents were well tolerated without development of antiviral resistance. CONCLUSIONS: Universal prophylaxis of CMV infection-following liver transplantation with aciclovir is more cost-effective than with ganciclovir.
Subject(s)
Acyclovir/administration & dosage , Acyclovir/economics , Cytomegalovirus Infections/prevention & control , Ganciclovir/administration & dosage , Ganciclovir/economics , Liver Transplantation , Adult , Age Distribution , Antiviral Agents/administration & dosage , Australia , Cost-Benefit Analysis , Cytomegalovirus Infections/epidemiology , Drug Costs , Female , Graft Rejection/prevention & control , Health Care Costs , Humans , Incidence , Male , Middle Aged , Postoperative Complications/prevention & control , Primary Prevention/economics , Primary Prevention/methods , Probability , Retrospective Studies , Sex Distribution , Statistics, Nonparametric , Treatment OutcomeABSTRACT
BACKGROUND AND AIMS: To determine response rate, side-effects and compliance in patients with chronic hepatitis C virus (HCV) infection following treatment with interferon-alpha-2b and ribavirin in a 'shared care' hospital clinic. METHODS: Data were collected prospectively on 81 patients treated with combination therapy for chronic HCV infection between 1999 and 2001. All had biochemical and virological evidence of active infection. All patients had undergone liver biopsy except haemophiliac patients. Patients infected with genotype 1 were treated for 12 months. Patients infected with genotypes 2 and 3 were treated for 6 months. Patient care was shared with the referring general practitioner. Intention to treat, end of treatment and sustained virological response (SVR) rates, side-effects and compliance were assessed. RESULTS: Eighty-one patients with chronic HCV infection were treated with combination therapy. The majority of HCV patients were genotype 1 (n = 46; 57%). There were 12 patients (15%) with cirrhosis. SVR rates were: (i) 24% for genotype 1, (ii) 58% for genotype 3 and (iii) 75% for genotype 2. SVR was achieved in three (23%) cirrhotic patients. Compliance with the treatment regimen was 98%. Seven per cent of patients were withdrawn from therapy prematurely because of side-effects. CONCLUSIONS: These 'shared care' clinic results compare well with controlled clinical trials using combination therapy for chronic HCV infection. Outcomes were poorer in genotype 1 patients and in patients with cirrhosis. Compliance with therapy was excellent because of the 'Shared Care Programme' with participation of general practitioners, psychiatrists and hepatitis C nurse practitioners in the management protocol.
Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Interferon-alpha/therapeutic use , Patient Compliance , Ribavirin/therapeutic use , Adult , Drug Therapy, Combination , Female , Genotype , Hepacivirus/genetics , Humans , Interferon alpha-2 , Male , Middle Aged , RNA, Viral/analysis , Recombinant ProteinsABSTRACT
End-stage liver disease associated with hepatitis C virus (HCV) infection is now the leading indication for liver transplantation in adults. However, reinfection of the graft is universal. We aimed to determine predictors of outcome of HCV-liver transplant recipients in the Australian and New Zealand communities. The following variables were analysed: demographic factors, coexistent pathology at the time of transplantation, HCV genotype, and donor age. Outcomes measures were: 1. mortality; 2. development of HCV-related complications, which were stage 3 or 4 fibrosis, or mortality from HCV-related graft failure, or both. Between January 1989 and December 30, 1999, 182 patients were transplanted for HCV-associated cirrhosis. The median follow-up period was 4 years (range, 0 to 13 years). Genotype data were available on 157 patients. The distribution of genotypes among the 157 patients was as follows: 36 (23%) genotype 1a, 30 (19%) genotype 1b, 4 (9%) genotype 1, 17 (11%) genotype 2, 41 (26%) genotype 3a, and 16 (10%) genotype 4. Eight (5%) patients were HCV-polymerase chain reaction (PCR)-negative (but HCV-antibody-positive). Donor age and genotype 4 were associated with an increased risk of retransplantation or death (P <.001 and.05, respectively). Meanwhile, donor age, genotype 4, and pretransplant excess alcohol were risk factors for the development of HCV-related complications (P =.004,.008, and.02, respectively). In contrast, patients with genotype 3a were less likely to develop HCV-related complications (P =.05). In a population of HCV liver transplant recipients with a heterogeneous genotype distribution, donor age, and genotype 4, were predictors of a worse outcome, whereas genotype 3 was associated with a more favorable outcome.
Subject(s)
Hepacivirus/genetics , Hepatitis C/complications , Liver Cirrhosis/surgery , Liver Cirrhosis/virology , Liver Transplantation , Adult , Aged , Aging , Female , Genotype , Graft Rejection/pathology , Graft Survival , Hepatitis C/mortality , Humans , Immunosuppression Therapy , Liver/pathology , Liver Transplantation/mortality , Male , Middle Aged , Prognosis , Recurrence , Reoperation , Survival Analysis , Tissue DonorsSubject(s)
Chemical and Drug Induced Liver Injury/diagnosis , Chemical and Drug Induced Liver Injury/etiology , Cholestasis/chemically induced , Platelet Aggregation Inhibitors/adverse effects , Ticlopidine/adverse effects , Cholestasis/diagnosis , Diagnosis, Differential , Humans , Male , Middle AgedABSTRACT
The outcome of fulminant hepatic failure without timely liver transplantation is poor. We describe a 19-year-old woman with fulminant hepatic failure due to acute hepatitis B infection who received a living donor liver transplant from her sister. The donor's recovery was uneventful, allowing hospital discharge on Day 6. Two months after transplantation the recipient developed a biliary stricture requiring surgery. One year after transplantation, her liver function was normal.
Subject(s)
Liver Failure/surgery , Liver Transplantation , Living Donors , Treatment Outcome , Adult , Female , Humans , Postoperative PeriodABSTRACT
The widespread use of the genotype assay that identifies the common C282Y mutation in the HFE gene has allowed an earlier diagnosis to be made in many subjects. A significant number of these patients may have no evidence of phenotypic disease and have a normal serum ferritin level. This phenomenon is more common when the genotype assay is used to screen populations rather than higher-risk groups such as family members of a proband with hereditary hemochromatosis. Moreover, patients with significant iron overload may be wild type for the C282Y mutation and have no other demonstrable mutation of the HFE gene. The HFE genotype assay has recently been found to give a false-positive C282Y homozygous result in half of the subjects in one population screening study due to the presence of a single nucleotide polymorphism (SNP) that interfered with primer binding in the PCR assay. The problem may be overcome by using alternate primers. A number of other groups have confirmed the finding but in a much smaller number of subjects, whereas others found that their assays were not affected by the SNP. The use of the HFE genotype assay as the sole diagnostic criterion for hereditary hemochromatosis is not recommended. The genotype assay should be used as an adjunct to the established methods of demonstrating iron overload and be viewed as a predictor of either the presence of iron overload or the subsequent development of iron overload during an individual's lifetime.
Subject(s)
Hemochromatosis/diagnosis , Hemochromatosis/genetics , Membrane Proteins , Female , HLA Antigens/genetics , Hemochromatosis Protein , Histocompatibility Antigens Class I/genetics , Homozygote , Humans , Male , Mutation , Polymerase Chain Reaction , Polymorphism, Restriction Fragment LengthABSTRACT
BACKGROUND: Iron stores in the body are thought to be regulated by a mechanism associated with the rate of iron absorption from the diet, with no significant role played by iron excretion. We report the existence of an iron excretory process that results in the loss of significant amounts of liver iron. METHODS AND RESULTS: Rats were fed 3% carbonyl iron for 9 weeks, which resulted in a 20-fold increase in liver non-haem iron. When the rats on this iron-loaded diet were switched to a low iron diet for 2 and 7 days, liver non-haem iron levels fell 30% and 45%, respectively. A similar fall in transferrin-bound plasma iron was also seen. As the liver iron had not redistributed to other body compartments, it was concluded that the iron had been excreted and that the excreted iron represented a loss of 22% and 28% in total body non-haem iron over 2 and 7 days, respectively. Ligation of the common bile duct in iron loaded rats that had been switched to the iron-deficient diet was accompanied by a similar loss of liver iron and also hepatocellular damage. In addition, measurement of enterocyte iron levels showed that only approximately 5% of the total iron excreted was found in these cells. CONCLUSION: Neither bile nor enterocytes play a significant role in iron excretion. The similarity in the degree of fall in transferrin-bound iron levels with a change in diet suggests that iron excretion involves the uptake and excretion of transferrin bound-iron, possibly by goblet cells. The observed hypertrophy of the intestinal mucosa associated with carbonyl iron feeding may facilitate hypersecretion of mucous and the excretion of this iron.
Subject(s)
Iron Overload/metabolism , Iron, Dietary/administration & dosage , Iron/metabolism , Animals , Body Weight , Common Bile Duct/physiology , Duodenum/metabolism , Enterocytes/metabolism , Goblet Cells/metabolism , Iron Overload/pathology , Ligation , Liver/metabolism , Liver/pathology , Male , Organ Size , Rats , Rats, Wistar , Spleen/metabolism , Spleen/pathologySubject(s)
HLA Antigens/genetics , Histocompatibility Antigens Class I/genetics , Membrane Proteins , False Positive Reactions , Hemochromatosis Protein , Molecular Sequence Data , Mutation , Oligonucleotides, Antisense , Polymerase Chain Reaction , Polymorphism, Genetic , Reproducibility of Results , TemperatureABSTRACT
BACKGROUND: A review of biliary tract complications was performed in 32 patients who underwent liver transplantation by the Western Australian Liver Transplantation Service during a 2-year period. METHODS: A review was made of patient data collected prospectively, and confirmed by retrospective casenote review. RESULTS: A total of 30 patients (31 grafts) survived more than 2 days after transplantation, and of these 28 had an end-to-end biliary anastomosis. Analysis of these 28 patients found that eight of 17 patients with T-tubes had complications: three leaks at T-tube removal; two strictures and leaks; and three strictures. Six of 11 patients without a T-tube had complications: one leak; three strictures and leaks; and two strictures. Predisposing factors were present in eight of the 14 patients with biliary tract complications: hepatic artery stenosis in three; and one each with hepatic artery thrombosis; biliary calculi; donor-recipient bile duct mismatch; severe cellular rejection: and prolonged postoperative hypotension. Acute rejection, steroid-resistant rejection and cytomegalovirus infection were all significantly more common in those patients with biliary tract complications compared with those without. There was no difference in cold ischaemic time or donor age. Twelve of the 14 patients with biliary complications required endoscopic stenting with or without balloon dilation, and eight patients required radiological percutaneous drainage of bile collections. Only one patient required biliary reconstruction and two patients required re-transplantation. One patient died of uncontrolled infection. Of three patients who underwent choledochojejunostomy, biliary leak developed in two patients, both of whom required operative biliary and hepatic repair. One of the three patients died from disseminated Aspergillus infection. The median total hospital stay of patients with biliary complications was 61 days (range: 30-180 days) compared with 33.5 days (range: 22-70 days) for patients without. Of patients with end-to-end biliary anastomosis, 50% had biliary tract complications and more than half of these had predisposing factors. The majority of biliary complications were managed without the need for surgery. CONCLUSION: A total of 50% of patients with end-to-end biliary anastomosis had biliary tract complications. Biliary strictures presented later than leaks, and the majority of these complications were managed without the need for surgery.
Subject(s)
Biliary Tract Diseases/etiology , Liver Transplantation/adverse effects , Adolescent , Adult , Aged , Anastomosis, Surgical/adverse effects , Anastomosis, Surgical/instrumentation , Arterial Occlusive Diseases/etiology , Aspergillosis/etiology , Bile Duct Diseases/etiology , Cholangiopancreatography, Endoscopic Retrograde , Choledochostomy/adverse effects , Choledochostomy/instrumentation , Cholelithiasis/etiology , Constriction, Pathologic/etiology , Cytomegalovirus Infections/etiology , Female , Follow-Up Studies , Graft Rejection/etiology , Graft Survival , Hepatic Artery/pathology , Humans , Hypotension/etiology , Intubation/adverse effects , Intubation/instrumentation , Male , Middle Aged , Prospective Studies , Retrospective Studies , Thrombosis/etiologyABSTRACT
BACKGROUND: The liver is the major iron storage organ in the body and, as a result, total body iron stores closely regulate hepatocyte iron uptake, storage and release. Transferrin, transferrin receptor and ferritin facilitate these processes. METHODS: Expression of the three proteins was localized by immunohistochemistry and in situ hybridization on normal, iron-loaded and iron-deficient rat livers. Gel shift assays were used to determine iron regulatory protein (IRP) binding activity. RESULTS: In the normal rat liver, all three proteins and mRNA were evenly distributed throughout the hepatic lobule. In iron-loaded liver, increased iron stores were found in a periportal distribution, coinciding with increased periportal protein levels of each protein. Periportal transferrin and ferritin mRNA levels were also increased. Hepatic transferrin and transferrin receptor expression was increased in iron deficiency compared with controls; however, despite no change in ferritin mRNA levels being found, ferritin protein was not detected. Hepatic IRP2 binding activity was decreased in iron loading and increased in iron deficiency. CONCLUSION: The combined findings of this study were that, in the dietary iron-loaded rat model, increased iron stores were localized to periportal hepatocytes and that these same hepatocytes also had increased ferritin, transferrin receptor and transferrin protein expression. This response suggests that additional, non-IRP control mechanisms may be involved in the regulation or stability of these proteins. In iron deficiency the inverse post-transcriptional regulation of ferritin and transferrin receptor was consistent with IRP regulation.